Cargando…

M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells

M3814, also known as nedisertib, is a potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor under phase 2 clinical trials. ABCG2 is a member of the ATP-binding cassette (ABC) transporter family that is closely related to multidrug resistance (MDR) in cancer treatment. In this study, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Zhuo-Xun, Peng, Zheng, Yang, Yuqi, Wang, Jing-Quan, Teng, Qiu-Xu, Lei, Zi-Ning, Fu, Yi-Ge, Patel, Ketankumar, Liu, Lili, Lin, Lizhu, Zou, Chang, Chen, Zhe-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235170/ https://www.ncbi.nlm.nih.gov/pubmed/32477940 http://dx.doi.org/10.3389/fonc.2020.00674

Ejemplares similares

Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells
por: Wu, Zhuo‐Xun, et al.
Publicado: (2020)

DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia
por: Carr, Michael I., et al.
Publicado: (2020)

Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro
por: Yang, Yuqi, et al.
Publicado: (2020)

MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study
por: Wu, Zhuo-Xun, et al.
Publicado: (2022)

DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer
por: Wang, Manni, et al.
Publicado: (2021)

Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells
por: Li, Yi-Dong, et al.
Publicado: (2020)

Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor
por: Wu, Zhuo-Xun, et al.
Publicado: (2021)

AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer
por: Liu, Kun, et al.
Publicado: (2021)

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
por: Ji, Ning, et al.
Publicado: (2019)

Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells
por: Wang, Jingqiu, et al.
Publicado: (2020)

Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
por: Zhang, Yongchao, et al.
Publicado: (2020)

OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Yang, Yuqi, et al.
Publicado: (2021)

Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
por: Wise, Hannah C., et al.
Publicado: (2019)

Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor
por: Wang, Jing-Quan, et al.
Publicado: (2020)

VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters
por: Ji, Ning, et al.
Publicado: (2018)

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Wu, Zhuo-Xun, et al.
Publicado: (2020)

Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer
por: Gordhandas, Sushmita B., et al.
Publicado: (2022)

Establishment and Characterization of a Novel Multidrug Resistant Human Ovarian Cancer Cell Line With Heterogenous MRP7 Overexpression
por: Wang, Jing-Quan, et al.
Publicado: (2021)

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
por: Feng, Weiguo, et al.
Publicado: (2020)

Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
por: Zhang, Wei, et al.
Publicado: (2018)

VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study
por: Narayanan, Silpa, et al.
Publicado: (2021)

Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2
por: Wang, De-Shen, et al.
Publicado: (2014)

The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance
por: Narayanan, Silpa, et al.
Publicado: (2021)

Overexpression of ABCC1 Confers Drug Resistance to Betulin
por: Chen, Xuan-Yu, et al.
Publicado: (2021)

Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells
por: Wu, Zhuo-Xun, et al.
Publicado: (2021)

Establishment and Characterization of an Irinotecan-Resistant Human Colon Cancer Cell Line
por: Wu, Zhuo-Xun, et al.
Publicado: (2021)

Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter
por: Gao, Hai-Ling, et al.
Publicado: (2020)

Long-Read Sequencing Annotation of the Transcriptome in DNA-PK Inactivated Cells
por: Song, Liwei, et al.
Publicado: (2022)

Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters
por: Zhang, Yun-Kai, et al.
Publicado: (2016)

Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells
por: Wang, Jing-Quan, et al.
Publicado: (2020)

Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells
por: Cui, Qingbin, et al.
Publicado: (2019)

DNA-PK as an Emerging Therapeutic Target in Cancer
por: Mohiuddin, Ismail S., et al.
Publicado: (2019)

Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells
por: Lei, Zi‐Ning, et al.
Publicado: (2021)

Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway
por: Liao, Xiaozhong, et al.
Publicado: (2020)

Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies
por: Li, Jun, et al.
Publicado: (2017)

PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study
por: Yang, Yuqi, et al.
Publicado: (2022)

BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance
por: Ashar, Yunali V., et al.
Publicado: (2020)

Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor
por: Yang, Yuqi, et al.
Publicado: (2020)

Anticancer effect of Indanone-based thiazolyl hydrazone derivative on p53 mutant colorectal cancer cell lines: An in vitro and in vivo study
por: Narayanan, Silpa, et al.
Publicado: (2022)

The multidrug transporter ABCG2: still more questions than answers
por: Horsey, Aaron J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jv9dp6q4q2u2d186su2d7cde6n